GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Innovative MedTech Inc (OTCPK:IMTH) » Definitions » ROC %

IMTH (Innovative MedTech) ROC % : -130.67% (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Innovative MedTech ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Innovative MedTech's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -130.67%.

As of today (2024-12-14), Innovative MedTech's WACC % is -3.72%. Innovative MedTech's ROC % is -109.14% (calculated using TTM income statement data). Innovative MedTech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Innovative MedTech ROC % Historical Data

The historical data trend for Innovative MedTech's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative MedTech ROC % Chart

Innovative MedTech Annual Data
Trend Oct10 Oct11 Oct12 Oct13 Oct14 Jun20 Jun21 Jun22 Jun23 Jun24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.88 -15.63 -306.73 -61.89 -107.06

Innovative MedTech Quarterly Data
Jul14 Oct14 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.05 -10.62 -61.75 -305.34 -130.67

Innovative MedTech ROC % Calculation

Innovative MedTech's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2024 is calculated as:

ROC % (A: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2023 ) + Invested Capital (A: Jun. 2024 ))/ count )
=-4.274 * ( 1 - 0% )/( (5.755 + 2.229)/ 2 )
=-4.274/3.992
=-107.06 %

where

Innovative MedTech's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-3.308 * ( 1 - 0% )/( (2.229 + 2.834)/ 2 )
=-3.308/2.5315
=-130.67 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovative MedTech  (OTCPK:IMTH) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Innovative MedTech's WACC % is -3.72%. Innovative MedTech's ROC % is -109.14% (calculated using TTM income statement data). Innovative MedTech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Innovative MedTech ROC % Related Terms

Thank you for viewing the detailed overview of Innovative MedTech's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative MedTech Business Description

Traded in Other Exchanges
N/A
Address
2310 York Street, Suite 200, Blue Island, IL, USA, 60406
Innovative MedTech Inc is a provider of health and wellness services. It develops, manufactures, and sells a variety of medical devices and supplies, including blood collection and infusion products, surgical instruments, and wound care products. The company operates in two divisions: technology and devices and Adult Day Services.
Executives
Merle Griff officer: Chief Executive Officer 2310 YORK ST, SUITE 200, BLUE ISLAND IL 60406
Eddie Dovner 10 percent owner 70 SE 4TH AVE, DELRAY BEACH FL 33483
Charles Everhardt director, 10 percent owner, other: Chairman of the Board 2310 YORK ST, STE 200, BLUE ISLAND IL 60406
Arthur Friedman 10 percent owner 280 MADISON AVE #1007, NEW YORK NY 10016
Marcia Roberts 10 percent owner 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Michael Jordan Friedman director, 10 percent owner, officer: President & CEO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Illuminate, Inc. 10 percent owner 881 KENNEDY BLVD., JERSEY CITL NJ 07002
A William Bodine director, officer: CFO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Dominick M Cingari director, officer: COO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Jay Odintz director 280 MADISON AVENUE, NEW YORK NY 10016
Vincent L Verdiramo director, officer: President 3163 KENNEDY BLVD, JERSEY CITY NJ 07306